Angiogenic Factors in Bronchopulmonary Dysplasia  by Huang, Hsin-Chun
Pediatrics and Neonatology (2015) 56, 367e368Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /www.pediatr -neonatol .comEDITORIALAngiogenic Factors in Bronchopulmonary
DysplasiaTremendous progress in neonatal intensive care and sur-
factant replacement therapy has dramatically improved
the survival rate of premature infants suffering from
respiratory distress syndrome.1 The risk of the develop-
ment of bronchopulmonary dysplasia (BPD), however, re-
mains high in premature infants.2 Although BPD was
known as postnatal injury from oxygen and mechanical
ventilation therapy in premature infants, it is now
recognized as a result of antenatal and perinatal factors
that interrupt lung development in extremely premature
infants.
The causes of aberrant lung development have been
studied widely. Research revealed that angiogenesis is
needed for adequate pulmonary vascular development that
could support normal alveolar lung growth. Vascular endo-
thelial growth factor (VEGF), a potent angiogenic factor,
was decreased in the lungs of preterm infants with fatal
BPD.3 Placenta growth factor (PlGF) is a 45- to 50-kDa
dimeric glycoprotein. It has been found in placenta,
endothelial cells, epithelial cells, and various tumor types.
Because of its high homology with VEGF, it was classified as
a member of the VEGF family of growth factors. VEGF
stimulates angiogenesis by stimulating the VEGF tyrosine
kinase receptor-2 (VEGFR-2), whereas PlGF potentiates the
angiogenic response to VEGF via stimulation of VEGFR-1.4 In
contrast to the role of VEGF in physiological and patho-
logical angiogenesis, the role of PlGF is limited to patho-
logical conditions, such as inflammation, ischemia, and
cancer.4 Soluble fms-like tyrosine kinase-1, also known as
VEGF receptor-1 (sFlt-1 or sVEGFR-1), is a tyrosine kinase
protein that disables proteins that cause blood vessel
growth. It binds and reduces free circulating levels of the
proangiogenic factors VEGF and PlGF.5
Pro- and antiangiogenic factors have been studied
regarding involvement in pathologic lung development. As
shown in the study of proangiogenic and antiangiogenic
factors in cord blood from premature infants with and
without BPD, PlGF, but not VEGF or sFlt-1, was higher in the
BPD group than the non-BPD group.6 This proangiogenichttp://dx.doi.org/10.1016/j.pedneo.2015.09.001
1875-9572/Copyright ª 2015, Taiwan Pediatric Association. Published bfactor may be an effective biomarker because it has the
capability to be detected in the early phase, or even before
BPD has developed, to avoid or diminish the injurious ef-
fects of BPD. The limitation of this biomarker is that its
concentration can be biased by an inflammatory status in
other parts of the body, because this is not lung specific. In
fact, this biomarker is neither universally accepted nor
used routinely in the clinical setting.
The serum proangiogenic factor PlGF followed a bell-
shaped curve with advancing gestational age, in which the
concentration increased during the first two trimesters and
decreased as pregnancy progressed to term in normal
pregnancy women7; whether this trend is found in the cord
blood of premature newborns requires a further large cohort
study for clarification. Furthermore, lower PlGF level was
found in women in whom preeclampsia developed than in
normal pregnancy, even prior to clinical presentation. By
contrast, PlGF level was higher in cord blood from infants
with BPD. In view of this, a population-based large cohort
study of very-low-birth-weight Taiwanese infants was
reviewed, and BPD occurred significantly less frequently in
the infants born to mothers with preeclampsia.8
BPD is a complicatedmultisystem disease. In the neonatal
period, it exhibits as severe respiratory distress, with a sig-
nificant effect on the quality of life of affected infants. Even
as infants grow, despite an improvement in their general
health, airflow limitation persists, lung function declines,
growth is slower, and cognitive ability is decreased.9,10
Currently, there is no specific or effective treatment for
BPD. Vitamin A, diuretics, caffeine, bronchodilators, stem
cells, etc. are the treatment choices. In addition, the
angiogenic factor was shown to enhance lung structure in a
rat model, but whether it has any potential implication for
the treatment of BPD requires further research.
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